LBS
仁新醫藥股份有限公司
LBS is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is LBS-008 (NDA accepted; priority review, Stargardt disease), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| LBS-008 | — | NDA accepted; priority review | Stargardt disease | United States | 2026-08-12 | Company disclosure |
| LBS-007 | — | Phase 1 / Phase 2; recruiting | Relapsed or Resistant Acute Leukaemias | Australia, China, Taiwan, United States | 2026-03-27 | Trial registry |
Key events
- LBS-008: NDA accepted; priority review
Related Drugnews articles
No related articles in this language.